Shares of Medtronic (NYSE: MDT) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device company announced its fiscal 2025 third-quarter results before the market opened.
Medtronic reported third-quarter revenue of $8.3 billion, up 2.5% year over year. This result came in slightly below the consensus Wall Street estimate of $8.33 billion. Diluted earnings per share (EPS) were $1.01 based on generally accepted accounting principles (GAAP). Its adjusted EPS was $1.39, up 7% year over year and higher than the average analysts' estimate of $1.35.
Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
Investors clearly focused more on the lower-than-expected revenue than the better-than-expected earnings. But just how worrisome is the company's revenue miss?
I don't think it's worrisome at all. CEO Geoff Martha explained in the earnings call that surgical revenue was hurt by "a change in U.S. distributor buying patterns." However, Martha said this disruption is expected to be resolved soon.
Importantly, Medtronic continues to project organic revenue growth in fiscal 2025 of between 4.75% and 5%. It also expects adjusted EPS in the current fiscal year of $5.44 to $5.50. The midpoint of this range is above the consensus Wall Street EPS estimate of $5.45.
Investors seeking strong growth probably won't find the company appealing even with its shares down following the third-quarter update. However, the stock could be attractive to income investors. Its forward dividend yield is 3.24%.
Medtronic also isn't far away from potentially joining the elite group known as Dividend Kings with its track record of 47 consecutive years of dividend increases.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
Learn more »
*Stock Advisor returns as of February 3, 2025
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.